Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Bal Pharma

BALPHARMA
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Bal Pharma Share price and Fundamental Analysis

View All Details
View All Details
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.
Company Incorporation1987
ChairmanNA
Head QuartersBangalore
Previous NameNA

Key Metrics

Market Cap (Cr)
157.52
PE Ratio
21.84
Industry P/E
34.52
PEG Ratio
-6.94
ROE
9.32%
ROCE
9.58%
ROA
2.16%
Total Debt (Cr)
144.61
Debt to Equity
1.94
Dividend Yield
1.21%
EPS
4.53
Book Value & P/B
70.67 x 1.4
Face Value
10
Outstanding Shares(Cr)
1.59
Current Ratio
2.34
EV to Sales
0.99

Stock Returns

1 Week-2.69%
1 Month+0.69%
6 Months-19.53%
1 Year-16.39%
3 Years+0.24%
5 Years+128.76%
no_data

No Stocks

Smart Score

2.2
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 50.86%

FIIs : 0.14%

DIIs : 0.00%

Public : 49.00%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Bal Pharma Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Bal Pharma Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.

BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.

The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named 'SERVETUS' has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.

The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores.

In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug's manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.

Bal Pharma Share Price

Bal Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Bal Pharma Market Cap

Market capitalization of Bal Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Bal Pharma is valued compared to its competitors.

Bal Pharma PE Ratio

Bal Pharma PE ratio helps investors understand what is the market value of each stock compared to Bal Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Bal Pharma PEG Ratio

The PEG ratio of Bal Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Bal Pharma ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Bal Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Bal Pharma ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Bal Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Bal Pharma Total Debt

Total debt of Bal Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Bal Pharma Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Bal Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Bal Pharma CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Bal Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Bal Pharma Technical Analysis

Technical analysis of Bal Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Bal Pharma Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Bal Pharma shares often struggle to rise above due to selling pressure.

Bal Pharma Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Bal Pharma ’s financial health and profitability.

Bal Pharma Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Bal Pharma Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Bal Pharma Financials

The financials of Bal Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Bal Pharma Profit and Loss Statements

The profit and loss statement of Bal Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Bal Pharma .

Bal Pharma Balance Sheet

The balance sheet presents a snapshot of Bal Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Bal Pharma Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App